"Across the industry, real-world evidence is becoming an essential component to evaluating the safety and effectiveness of drug therapies and ultimately to delivering therapeutic advances. However, one of the most significant barriers to generating real-world evidence is overcoming limitations of single data sources."
Jamie Macdonald, CEO, Parexel, which partnered with Datavant to provide Parexel with the ability to link disparate datasets to drive the complex analyses necessary for providing innovative scientific and clinical data strategies
"The receptors already have a regulatory function. We want to modulate that. The space, we believe, is getting a lot of interest, so we are being quiet for now about the specifics."
Eliot Charles, executive chair of Mirobio Ltd., which has spun out of Oxford University to develop antibody-based therapies designed to activate immune checkpoint receptors in the treatment of autoimmune disorders
"We plan to select the investee companies through regional biomedical industrial complexes. Using the fund, Upin & Co. will support Korea's promising bio ventures to grow major competencies, license in and out and enter the global market. The portfolio will mainly consist of new drug developers. Developing first-in-class drugs is not a necessary criterion for selection, but the investee companies should be innovative biomedical R&D firms."
Ohseung Kwon, chairman and founder, Upin & Co. Ltd., a fund and asset management company, headquartered in London, that plans to invest a total of KRW2 trillion (US$1.7 billion) over three years in the South Korean biopharma industry